What is MIPI?
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is a validated prognostic scoring system designed specifically for patients with newly diagnosed mantle cell lymphoma (MCL). It was developed by Hoster et al. (2008) using data from large randomized clinical trials conducted by the European MCL Network.
MIPI incorporates four independent prognostic factors: patient age, Eastern Cooperative Oncology Group (ECOG) performance status, serum lactate dehydrogenase (LDH) level, and white blood cell (WBC) count. These factors were selected because they independently predicted overall survival in multivariate analyses.
The MIPI is specifically designed for MCL and should not be used for other lymphoma subtypes, which have their own prognostic indices (e.g., IPI for diffuse large B-cell lymphoma, FLIPI for follicular lymphoma).
MIPI Formula
Where:
- Age: Patient age in years at diagnosis
- ECOG: 0.6978 is added if ECOG performance status is 2, 3, or 4 (i.e., ≥2)
- LDH: Serum lactate dehydrogenase normalized to the upper limit of normal (ULN) of the local laboratory
- WBC: White blood cell count in ×10&sup9;/L (= ×10³/µL)
Risk Group Classification
| Risk Group | MIPI Score | Median OS | 5-year OS | % of Patients |
|---|---|---|---|---|
| Low Risk | < 5.7 | Not reached / >60 months | ~60% | ~44% |
| Intermediate Risk | 5.7 – 6.2 | ~51 months | ~35% | ~35% |
| High Risk | > 6.2 | ~29 months | ~20% | ~21% |
MCL Risk Stratification Diagram
Combined MIPI (MIPI-c)
The combined MIPI (MIPI-c) incorporates the Ki-67 proliferation index in addition to the four standard MIPI variables. Ki-67 is a nuclear protein associated with cellular proliferation, and its expression percentage reflects the growth fraction of the tumor.
In MCL, a high Ki-67 index (≥30%) is a strong adverse prognostic factor. The MIPI-c was shown to provide improved risk discrimination compared to the standard MIPI, particularly in reclassifying patients from intermediate to high risk. When Ki-67 data is available, the MIPI-c should be preferred.
In practice, the MIPI-c further stratifies patients into low, low-intermediate, high-intermediate, and high risk groups based on both the standard MIPI score and the Ki-67 percentage.
Mantle Cell Lymphoma Overview
Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma that accounts for approximately 5–7% of all non-Hodgkin lymphomas. It is characterized by the translocation t(11;14)(q13;q32), which leads to overexpression of cyclin D1. MCL typically presents in older adults (median age 65–70) with a male predominance (3:1 ratio).
MCL has a wide clinical spectrum, ranging from indolent leukemic presentations to aggressive nodal disease. The majority of patients present with advanced-stage disease (stage III or IV), often with bone marrow involvement, splenomegaly, and gastrointestinal tract infiltration.
Despite advances in treatment including intensive chemotherapy, autologous stem cell transplantation, BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib), and CAR-T cell therapy, MCL remains generally incurable with conventional approaches. The MIPI helps identify patients who may benefit from more intensive initial therapy versus those who may do well with less aggressive approaches.
Treatment Implications
| Risk Group | Treatment Approach | Key Considerations |
|---|---|---|
| Low Risk | Standard immunochemotherapy (R-CHOP, BR); watch and wait in select indolent cases | May not require transplant consolidation; longer remissions expected |
| Intermediate Risk | Intensive immunochemotherapy; consider transplant consolidation | Benefit from cytarabine-containing regimens; maintenance rituximab improves outcomes |
| High Risk | Aggressive therapy; clinical trials; consider novel agents upfront | Poor prognosis with conventional therapy; BTK inhibitors and CAR-T may be considered earlier |
Worked Example
A 65-year-old patient with ECOG 1, LDH 250 U/L (ULN 250), and WBC 8.0 ×10&sup9;/L:
This score of 3.15 falls in the Low Risk category (MIPI < 5.7). The patient has a favorable prognosis with median overall survival that is not reached in clinical studies, and an estimated 5-year overall survival of approximately 60%.
Frequently Asked Questions
Is MIPI applicable to relapsed MCL?
MIPI was developed and validated for patients with newly diagnosed MCL. At relapse, other factors such as duration of first remission, TP53 mutation status, and response to prior therapy may be more relevant. The simplified MIPI can still provide some prognostic information at relapse, but it has not been formally validated in this setting.
What is the significance of Ki-67 in MCL?
Ki-67 is one of the strongest prognostic factors in MCL. Patients with Ki-67 ≥ 30% have significantly worse outcomes. The blastoid variant of MCL typically has very high Ki-67 (≥50%) and carries the worst prognosis. When available, Ki-67 should be incorporated into risk assessment using the MIPI-c.
Should treatment decisions be based solely on MIPI?
No. MIPI provides valuable prognostic information but treatment decisions should consider multiple factors including patient comorbidities, organ function, patient preferences, TP53 mutation status, histologic variant (classic vs. blastoid), and availability of clinical trials. MIPI is a tool to inform discussions, not a prescriptive treatment algorithm.
How does MIPI compare to IPI?
The International Prognostic Index (IPI) was designed for aggressive NHL (primarily DLBCL). While IPI can be applied to MCL, it has lower discriminatory power than MIPI for this specific disease. MIPI was specifically calibrated for MCL biology and provides better risk stratification for this lymphoma subtype.